National Cancer Institute (NCI). Cancer stat facts: prostate cancer. Surveillance, Epidemiology, and End Results Program (SEER). https://seer.cancer.gov/statfacts/html/prost.html.

Berruti A, Bracarda S, Caffo O, Cortesi E, D’Angelillo R, Del Re M, et al. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives. Cancer Treat Rev. 2023;115:102525.

Article  CAS  PubMed  Google Scholar 

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer. Version 1.2023. September, 2022. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

Rice MA, Malhotra SV, Stoyanova T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol. 2019;9:801.

Article  PubMed  PubMed Central  Google Scholar 

Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013;31:3800–6.

Article  PubMed  PubMed Central  Google Scholar 

Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402–18.

Article  PubMed  PubMed Central  Google Scholar 

Saad F, Bogemann M, Suzuki K, Shore N. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. Prostate Cancer Prostatic Dis. 2021;24:323–34.

Article  PubMed  PubMed Central  Google Scholar 

ERLEADA®. Prescribing information. Janssen Products, LP. 2023. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/ERLEADA-pi.pdf.

NUBEQA®. Prescribing information. Bayer HealthCare Pharmaceuticals Inc. 2022. https://labeling.bayerhealthcare.com/html/products/pi/Nubeqa_PI.pdf?inline=.

XTANDI®. Prescribing information. Astellas Pharma Inc. 2022. https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf.

Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. (2023). https://doi.org/10.1097/JU.0000000000003452.

Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119–34.

Article  CAS  PubMed  Google Scholar 

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408–18.

Article  CAS  PubMed  Google Scholar 

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235–46.

Article  CAS  PubMed  Google Scholar 

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383:1040.

Article  CAS  PubMed  Google Scholar 

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79:150–8.

Article  CAS  PubMed  Google Scholar 

Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197–206.

Article  CAS  PubMed  Google Scholar 

Oudard S, Hadaschik B, Saad F, Cella D, Basch E, Graff JN, et al. Health-related quality of life at the SPARTAN final analysis of apalutamide for nonmetastatic castration-resistant prostate cancer patients receiving androgen deprivation therapy. Eur Urol Focus. 2022;8:958–67.

Article  PubMed  Google Scholar 

Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1404–16.

Article  CAS  PubMed  Google Scholar 

Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur J Cancer. 2021;154:138–46.

Article  CAS  PubMed  Google Scholar 

Tombal B, Saad F, Penson D, Hussain M, Sternberg CN, Morlock R, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:556–69.

Article  CAS  PubMed  Google Scholar 

Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 2017;35:3097–104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Nonmetastatic castration-resistant prostate cancer: considerations for metastasis-free survival endpoint in clinical trials — Guidance for Industry. August 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonmetastatic-castration-resistant-prostate-cancer-considerations-metastasis-free-survival-endpoint.

Brave M, Weinstock C, Brewer JR, Chi DC, Suzman DL, Cheng J, et al. An FDA review of drug development in nonmetastatic castration-resistant prostate cancer. Clin Cancer Res. 2020;26:4717–22.

Article  CAS  PubMed  Google Scholar 

Beaver JA, Kluetz PG, Pazdur R. Metastasis-free survival - a new end point in prostate cancer trials. N. Engl J Med. 2018;378:2458–60.

Article  PubMed  Google Scholar 

Cattrini C, Caffo O, De Giorgi U, Mennitto A, Gennari A, Olmos D, et al. Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a critical review. Cancers (Basel). 2022;14.

Shore ND, Luz MdA, Ulys A, Ortiz JA, Srinivasan S, Kurland E, et al. Long-term safety and tolerability of darolutamide and duration of treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the ARAMIS rollover study. J Clin Oncol. 2023;41:147.

Article  Google Scholar 

Halabi S, Jiang S, Terasawa E, Garcia-Horton V, Ayyagari R, Waldeck AR, et al. Indirect comparison of darolutamide versus apalutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer. J Urol. 2021;206:298–307.

Article  PubMed  Google Scholar 

Maggi M, Salciccia S, Del Giudice F, Busetto GM, Falagario UG, Carrieri G, et al. A systematic review and meta-analysis of randomized controlled trials with novel hormonal therapies for non-metastatic castration-resistant prostate cancer: an update from mature overall survival data. Front Oncol. 2021;11:700258 https://doi.org/10.3389/fonc.2021.700258

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mulati Y, Fan Y, Yu W, Zhang Q, He Z. Novel androgen receptor inhibitors in non-metastatic, castration-resistant prostate cancer: a systematic review and network meta-analysis. Front Oncol. 2021;11:733202 https://doi.org/10.3389/fonc.2021.733202

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benoist GE, van Oort IM, Smeenk S, Javad A, Somford DM, Burger DM, et al. Drug-drug interaction potential in men treated with enzalutamide: mind the gap. Br J Clin Pharm. 2018;84:122–9.

Article  CAS  Google Scholar 

Conde-Estevez D, Henriquez I, Munoz-Rodriguez J, Rodriguez-Vida A. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2022;18:601–13.

Article  CAS  PubMed  Google Scholar 

Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57–65.

Article  PubMed  Google Scholar 

Nightingale G, Skonecki E, Boparai MK. The impact of polypharmacy on patient outcomes in older adults with cancer. Cancer J. 2017;23:211–8.

PubMed  Google Scholar 

Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12:601–10.

Article  CAS  PubMed  Google Scholar 

Derendorf H, Schmidt S. Rowland and Tozer’s Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. Fifth edn. (Wolters Kluwer, 2020).

Mohamed MR, Mohile SG, Juba KM, Awad H, Wells M, Loh KP, et al. Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer. Cancer. 2023;129:1096–104.

Article  CAS  PubMed  Google Scholar 

Ramsdale E, Mohamed M, Yu V, Otto E, Juba K, Awad H, et al. Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment. Oncologist. 2022;27:e580–e8.

Article  PubMed  PubMed Central  Google Scholar 

Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, et al. Management of patients with advanced prostate cancer. part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023;83:267–93.

Article  CAS  PubMed  Google Scholar 

Figueiredo A, Costa L, Mauricio MJ, Figueira L, Ramos R, Martins-da-Silva C. Nonmetastatic castration-resistant prostate cancer: current challenges and trends. Clin Drug Investig. 2022;42:631–42.

Article  PubMed  PubMed Central  Google Scholar 

Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54:1057–69.